pharma · Idiopathic Hypersomnia · Prader-Willi Syndrome · HRMY
Harmony Biosciences Holdings
Harmony Biosciences Holdings patent portfolio — 6 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US
- Founded
- 2017
- Employees
- 332
- Programs
- 21
- Drugs
- 14
- Patents
- 6
Harmony Biosciences Holdings patents
6 pharmaceutical patents indexed for Harmony Biosciences Holdings. 0 expire within 24 months.
Harmony Biosciences Holdings has 6 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12226373
Treatment of fragile X syndrome with cannabidiol
granted -
US 12213951
Treatment of autism with cannabidiol
granted -
US 12186282
Treatment of 22Q11.2 deletion syndrome with cannabidiol
granted -
US 9296774
Halogenated dideoxy sugar derivates, preparation method and application thereof
granted -
US 7625575
Dermatological composition
granted -
US 7582307
Dermatological composition
granted
Frequently asked questions
How many patents does Harmony Biosciences Holdings have?
6 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Harmony Biosciences Holdings patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.